| HOME >> BIOLOGY >> TECHNOLOGY |
Ordinary shares 13 14
Additional paid-in capital 260,107 268,333
Retained earnings 94,466 124,310
Accumulated other comprehensive loss 19,436 39,067
Total shareholders' equity 374,022 431,724
Total liabilities and shareholders' equity 446,714 700,212
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three months ended June 30, Six months ended June 30
2007 2008 2007 2008
US$ US$ US$ US$
(unaudited) (unaudited) (unaudited) (unaudited)
(In thousands, except (In thousands, except
share and per share data) share and per share data)
Net revenues
-PRC 36,280 57,846 63,159 100,637
- International 36,752 87,821 64,317 132,458
Net revenues 73,032 145,667 127,476 233,095
Cost of revenues (note
2) (32,104) (68,695) (55,985) (106,697)
Gross profit 40,928 76,972 71,491 126,398
Selling expenses (note
2) (10,529) (20,639) (16,722) (31,123)
General and
administrative
expenses (note 2) (2,714) (9,588) (5,700) (12,202)
Research and
development expenses
(note 2) (6,407) (12,322) (11,726) (20,744)
Expense of in-progress
research &
development
'/>"/>
| SOURCE Mindray Medical International Limited Copyright©2008 PR Newswire. All rights reserved |